Pharsight

Qelbree generic

Qelbree is owned by Supernus Pharms. Qelbree contains viloxazine hydrochloride. Qelbree was authorised for market use on 02 April, 2021. The medication is available in a capsule, extended release; oral dosage form.

When will Qelbree generic be available?

The generic version of Qelbree is likely to be released after 07 February, 2033, when the last patent (US9662338 titled 'Formulations of viloxazine') expires. However, drug patent challenges against Qelbree can be filed from 2025-04-02.

Qelbree uses

Qelbree can be used for the treatment of attention deficit hyperactivity disorder (ADHD). The active ingredient in Qelbree, viloxazine hydrochloride, is effective in managing symptoms of ADHD.

Qelbree patent expiration

Qelbree holds a total of 5 drug patents, none of which have expired. The last patent is set to expire on 07 February, 2033. The generic version of Qelbree will likely be available after this date. Below are the details of the patent:

Litigations filed on Qelbree

Qelbree dosage

Want to ask something?